BACKGROUND: Although rituximab-based chemoimmunotherapy (CIT) has substantially improved clinical outcomes in chronic lymphocytic leukemia (CLL), only 40% to 50% of patients achieve a complete remission (CR). There remains interest in identifying new approaches to improve the effectiveness of CIT. Ofatumumab is a fully human anti-CD20 monoclonal antibody with greater apparent single-agent activity than rituximab in CLL patients. METHODS: Previously untreated CLL patients in need of therapy received 6 cycles of CIT induction with pentostatin, cyclophosphamide, and ofatumumab (PCO) followed by response assessment. RESULTS: Of the 48 patients enrolled, 77% completed PCO induction. Adverse events during induction included grade 3+ hematologic toxicity (27%) and grade 3+ nonhematologic toxicity (23%). Median CD4 count after induction and 6 months later were 186 × 10(6)/L and 272 × 10(6) /L. The overall response rate was 96% (46 of 48 patients), and the CR rate was 46% (22 of 48 patients). Among the 38 patients who underwent minimal residual disease evaluation, 7 (18%) were negative for minimal residual disease. After median follow-up of 24 months, 10 (21%) patients have progressed and 8 (17%) have required retreatment. The efficacy and toxicity of ofatumumab-based CIT compare favorably to our historical trials of rituximab-based CIT using an identical chemotherapy backbone (n = 64). Time to retreatment also appeared longer for ofatumumab-based CIT (free of retreatment at 24 months: 86% [95% confidence interval = 75-99] versus 68% [95% confidence interval = 56-81] for rituximab-based CIT). CONCLUSIONS: Ofatumumab-based CIT is well tolerated in patients with previously untreated CLL. The efficacy of ofatumumab-based CIT compares favorably to historical trials of rituximab-based CIT, suggesting randomized trials comparing ofatumumab-based CIT and rituximab-based CIT should be considered.
BACKGROUND: Although rituximab-based chemoimmunotherapy (CIT) has substantially improved clinical outcomes in chronic lymphocytic leukemia (CLL), only 40% to 50% of patients achieve a complete remission (CR). There remains interest in identifying new approaches to improve the effectiveness of CIT. Ofatumumab is a fully human anti-CD20 monoclonal antibody with greater apparent single-agent activity than rituximab in CLL patients. METHODS: Previously untreated CLL patients in need of therapy received 6 cycles of CIT induction with pentostatin, cyclophosphamide, and ofatumumab (PCO) followed by response assessment. RESULTS: Of the 48 patients enrolled, 77% completed PCO induction. Adverse events during induction included grade 3+ hematologic toxicity (27%) and grade 3+ nonhematologic toxicity (23%). Median CD4 count after induction and 6 months later were 186 × 10(6)/L and 272 × 10(6) /L. The overall response rate was 96% (46 of 48 patients), and the CR rate was 46% (22 of 48 patients). Among the 38 patients who underwent minimal residual disease evaluation, 7 (18%) were negative for minimal residual disease. After median follow-up of 24 months, 10 (21%) patients have progressed and 8 (17%) have required retreatment. The efficacy and toxicity of ofatumumab-based CIT compare favorably to our historical trials of rituximab-based CIT using an identical chemotherapy backbone (n = 64). Time to retreatment also appeared longer for ofatumumab-based CIT (free of retreatment at 24 months: 86% [95% confidence interval = 75-99] versus 68% [95% confidence interval = 56-81] for rituximab-based CIT). CONCLUSIONS:Ofatumumab-based CIT is well tolerated in patients with previously untreated CLL. The efficacy of ofatumumab-based CIT compares favorably to historical trials of rituximab-based CIT, suggesting randomized trials comparing ofatumumab-based CIT and rituximab-based CIT should be considered.
Authors: J Golay; M Lazzari; V Facchinetti; S Bernasconi; G Borleri; T Barbui; A Rambaldi; M Introna Journal: Blood Date: 2001-12-01 Impact factor: 22.113
Authors: Tait D Shanafelt; Alan G Ramsay; Clive S Zent; Jose F Leis; Han W Tun; Timothy G Call; Betsy LaPlant; Deborah Bowen; Adam Pettinger; Diane F Jelinek; Curtis A Hanson; Neil E Kay Journal: Blood Date: 2013-03-14 Impact factor: 22.113
Authors: J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: S M O'Brien; H Kantarjian; D A Thomas; F J Giles; E J Freireich; J Cortes; S Lerner; M J Keating Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter Journal: N Engl J Med Date: 2000-12-28 Impact factor: 91.245
Authors: K R Rai; B L Peterson; F R Appelbaum; J Kolitz; L Elias; L Shepherd; J Hines; G A Threatte; R A Larson; B D Cheson; C A Schiffer Journal: N Engl J Med Date: 2000-12-14 Impact factor: 91.245
Authors: B Bellosillo; N Villamor; A López-Guillermo; S Marcé; J Esteve; E Campo; D Colomer; E Montserrat Journal: Blood Date: 2001-11-01 Impact factor: 22.113
Authors: M Leporrier; S Chevret; B Cazin; N Boudjerra; P Feugier; B Desablens; M J Rapp; J Jaubert; C Autrand; M Divine; B Dreyfus; K Maloum; P Travade; G Dighiero; J L Binet; C Chastang Journal: Blood Date: 2001-10-15 Impact factor: 22.113
Authors: John C Byrd; Bercedis L Peterson; Vicki A Morrison; Kathleen Park; Robert Jacobson; Eva Hoke; James W Vardiman; Kanti Rai; Charles A Schiffer; Richard A Larson Journal: Blood Date: 2002-07-05 Impact factor: 22.113
Authors: Junji Uchida; Yasuhito Hamaguchi; Julie A Oliver; Jeffrey V Ravetch; Jonathan C Poe; Karen M Haas; Thomas F Tedder Journal: J Exp Med Date: 2004-06-21 Impact factor: 14.307
Authors: Samantha M Jaglowski; Jeffrey A Jones; Veena Nagar; Joseph M Flynn; Leslie A Andritsos; Kami J Maddocks; Jennifer A Woyach; Kristie A Blum; Michael R Grever; Kelly Smucker; Amy S Ruppert; Nyla A Heerema; Gerard Lozanski; Mona Stefanos; Brian Munneke; Jamie-Sue West; Jutta K Neuenburg; Danelle F James; Nathan Hall; Amy J Johnson; John C Byrd Journal: Blood Date: 2015-06-26 Impact factor: 22.113
Authors: Nisar A Baig; Ronald P Taylor; Margaret A Lindorfer; Amy K Church; Betsy R LaPlant; Adam M Pettinger; Tait D Shanafelt; Grzegorz S Nowakowski; Clive S Zent Journal: J Immunol Date: 2014-01-15 Impact factor: 5.422